No differences were observed according to ABCG2 Q141K and V12M genotype in patient characteristics, disease characteristics, response, survival, or hematology toxicity profiles in patients with DLBCL who received frontline R-CHOP chemotherapy.
Cox proportional hazards analyses demonstrated that the GG genotype of <i>ABCG2</i> rs2231137 and <i>NCF4</i> rs1883112 were risk factors in DLBCL patients.